Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.

Eli Lilly's stock fell 4.58% following weak trial results from Novo Nordisk’s obesity drug, shaking investor confidence in ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

Health-care companies fell as traders retreated from some of the highest risk issues.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Shares of Novo Nordisk’s (NVO) are down over 9% at the time of writing after the company announced the results from its latest weight-loss drug ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...